For Investors
Outlined in the chart below, MaRS Innovation has established an effective process to review, research, support and help transform disclosures from our member institutions into marketable products and processes. Our goal is always to build on an invention’s value, focusing on inventions in the life sciences, physical sciences, medical devices and ICT.
MaRS Innovation offers investors a crucial advantage in reducing the risk associated with early-stage participation: the discoveries we represent are only the most patentable and high potential inventions from 17 of Toronto’s top universities and research institutes. We also adhere to strict due diligence in evaluating our members’ technologies, their IP status and market potential – before they are ever presented to potential investors.
During the first two years of operation, MaRS Innovation reviewed more than 400 disclosures. After extensive selection process, 40 proposals were adopted for further development towards commercialization. All of them are now at different stages of early commercialization, which we have accelerated by investing in foundational funding; patent review and filing; as well as initial technology development. (See Assets Under Development).
In reducing the risk of these investments at their most vulnerable stage, we are able to improve their potential upside in a number of ways:
By capitalizing on our extensive experience in early-stage IP.
By bundling related discoveries from our members that target a specific disease or problem; a range of diseases or treatment options; or that address a range of applications in ICT or engineering.
By leveraging the value from the sizeable public commitment to MaRS Innovation, and thereby creating a healthier investment environment for early-stage enterprises.
By combining both the scientific case and the business case for investors’ consideration.
